Compare IDEXX Laboratories, Inc. (IDXX) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Boston Beer Company Inc — how do they compare? IDEXX Laboratories, Inc. trades at $571.7 (market cap $46.22B), while Boston Beer Company Inc trades at $183.7 (market cap $1.86B). The key difference: IDEXX Laboratories, Inc. is far larger — about 24.8× Boston Beer Company Inc's market cap. Which is the better fit depends on your goals.
| IDXX | SAM | |
|---|---|---|
Market Cap | $46.22B | $1.86B |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $260.05 |
52-Week Low | $526.44 | $161.08 |
Enterprise Value | $47.12B | $1.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Boston Beer Company (SAM) trades at $181.95, up 0.53% with bearish technical signals despite recent earnings volatility. The stock shows mixed fundamentals with a P/E of 22.66 and P/S of 0.99, but faces profitability challenges with negative net income margin (-3.64%) and ROE (-8.61%). Recent Q2 2026 earnings missed estimates at $3.65 vs. $4.83 expected, while operating cash flow remains strong at $270M in 2025. Analyst sentiment is cautious with 72% hold ratings amid declining volumes and competitive pressures.
Outlook remains challenging with weak demand impacting core brands, though spirits-based RTD growth and margin improvements offer some support. The consensus price target of $207.33 suggests 14% upside potential, but investors face risks from sustained volume declines, rising marketing costs, and negative earnings growth projections for 2026. The stock's current technical position near pivot point resistance at $182 requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
